Serazym® Anti-SARS-CoV-2 RBD IgG
The entry of SARS-CoV-2 into its target cells depends on binding between the receptor-binding domain (RBD) of the viral spike protein and its cellular receptor, angiotensin-converting enzyme 2. Many investigations show a clear correlation between the presence of neutralizing antibodies and the detection of RBD-specific antibodies. To improve the SARS-CoV-2 antibody diagnostic and the detection of potentially neutralizing or protective antibodies, the Seramun Diagnostica GmbH has successfully developed an ELISA which is able to detect SARS-CoV-2-RBD-specific IgG antibodies. This Anti-SARS-CoV-2-RBD ELISA has so far been tested with 64 sera of COVID-19 patients and 218 negative blood donor sera (incl. Control groups → CMV, EBV, HBV, HCV, RF, pregnant woman). A Sensitivity of 90.6% and specificity of 100% were determined. RBD is a highly specific antigen for the SARS-CoV-2-antibody diagnostic. Antibody-crossreactivities with other human- and animal-pathogenic coronaviruses are unlikely. Semi-quantification of RBD-specific antibodies is possible with the assay and of increasing importance in the context of vaccination control. Furthermore, the assay is applicable for animal sera e.g. monkey, mouse, and hamster for vaccine-, drug-research and veterinary research.